Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
230
resultados
Última actualización
11/03/2026 [07:04:00]
Resultados 150 a 175 de 230
Resumen de: US20260053848A1
There is provided herein an oral formulation comprising: (a) water; (b) porous silica particles having pores in the mesoporous range; and (c) a thickening agent, wherein the average pore size of the pores in the mesoporous range is from about 7.0 to about 25.0 nm; and the thickening agent is selected from xanthan gum and microcrystalline cellulose or a mixture thereof. There are also provided uses of such formulations.
Resumen de: US20260053753A1
A method for promoting the controlled binding and release of a bioactive or pharmaceutical agent from a composition comprising silicon nanoparticles, wherein the silicon nanoparticles comprise at least 50% by weight silicon, the method comprising treating the surface of the silicon nanoparticles with at least one lipid, and treating the surface of the silicon nanoparticles with at least one amino acid, wherein the ratio of lipid to silicon is from 1:1 to 15:1. Also related compositions and methods.
Resumen de: US20260053754A1
A kaempferol-mesenchymal stem cell membrane biomimetic nano-material allowing for more accurate targeting to injured issues is provided. The biomimetic nano-material is simple in preparation method, high in universality, and suitable for large-scale production, mesenchymal stem cell membranes are used to improve the biocompatibility and targeting ability of carriers and increase the in vivo circulation time of drugs; the biomimetic nano-material allows for targeted delivery of kaempferol to the liver, providing a novel treatment method for ALF.
Resumen de: US20260054267A1
The present invention relates to methods for producing particles of a biologically active material using dry milling processes as well as compositions comprising such materials, medicaments produced using said biologically active materials in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of said biologically active materials administered by way of said medicaments.
Resumen de: US20260053957A1
The present invention generally relates to the field of ultrasound contrast-agents (USCA). In particular, it relates to a freeze-dried composition comprising an amphiphilic lipid compound comprising a phospholipid, a fluorinated compound in liquid form and a freeze-drying protecting component which may be reconstituted for preparing a suspension of nanodroplets useful in diagnostic or therapeutic applications. It further relates to the method for the preparation of such freeze-dried composition.
Resumen de: US20260053933A1
The present invention provides nuclease-resistant nucleic acid nanostructures, pharmaceutical compositions thereof, pharmaceutical and diagnostic uses thereof as well as a method of producing nucleic acid nanostructures.
Resumen de: US20260055429A1
A nanoparticle for delivery of mRNA to cell, comprising a core comprising a polyethylenimine polymer having fluorinated groups covalently coupled thereto and with mRNA reversibly associated therewith, and a shell surrounding the core comprising heparin. Ij some embodiments, the nanoparticle comprises a targeting agent associated with the shell, wherein the targeting agent is selected from the group consisting of agents that bind to receptors overexpressed on tumor cells, agents that bind to cell surf ace antigens that are expressed on pluripotent stem cells, agents that bind to cell surface antigens on T cells, and agents that bind to antigens presented by MHO molecules. Pharmaceutical compositions that include the nanoparticle and methods for using the nanoparticle for transfecting cells are provided
Resumen de: US20260055335A1
The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids are engineered with improved stability to oxidative degradation while in storage, while retaining high transfection activity or potency in cells. These lipids are designed to be biodegradable, thus improving the tolerability of nanoparticles formed with them in vivo. In addition, targeting of these nanoparticles in a highly specific manner to dendritic cells is provided for through inclusion of antibody conjugates directed against cell surface receptors.
Resumen de: US20260055200A1
The present invention relates to combination therapies for treating cancer, optionally chemotherapy-resistant cancers, in a subject. The combination therapies comprise (a) an antibody or antigen-binding portion thereof that specifically binds to CD40, and (b) chemotherapy. The invention also relates to pharmaceutical compositions, kits and methods of using such therapies.
Resumen de: US20260055050A1
The disclosure features novel lipids and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
Resumen de: US20260055047A1
Prostacyclin compounds and compositions comprising the same are provided herein. Specifically, prostacyclin compounds comprising treprostinil covalently linked to a linear C5-C18 alkyl, branched C5-C18 alkyl, linear C2-C18 alkenyl, branched C3-C18 alkenyl, aryl, aryl-C1-C18 alkyl or an amino acid or a peptide (e.g., dipeptide, tripeptide, tetrapeptide) are described. The linkage, in one embodiment, is via a carbamate, amide or ester bond. Prostacyclin compounds provided herein can also include at least one hydrogen atom substituted with at least one deuterium atom. Methods for treating pulmonary hypertension (e.g., pulmonary arterial hypertension) and portopulmonary hypertension are also provided.
Resumen de: AU2024339588A1
Formulated and/or co-formulated liposomes, lipid nanoparticle (LNP) and solid-lipid nanoparticles (SLNP) comprising TB Prodrugs and methods of making the LNPs and SLNPs are disclosed herein. The TB prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit ALK5. The TB Prodrugs can be formulated and/or co-formulated into a nanocarrier to provide a method of treating cancer, immunological disorders, and other diseases by utilizing a targeted drug delivery vehicle.
Resumen de: WO2025080572A1
A compound having the structure (I), (II), (III), or (IV) is provided: (I), (II), (III), (IV) ) where in these structures, (I), (II), (III), and (IV), each R1 is independently selected from aliphatic alkyl C4-C100 groups optionally substituted with one or more of alkenyl, alkynyl, hydroxyl, amide, ester, and/or ether groups; R2 is selected from -OCH2CH2-p or (A); R3 is selected from Formula (V) and Formula (VI): (V, (VI). M+ is selected from an alkali metal ion, an alkaline earth metal ion, or a primary, secondary or tertiary ammonium ion; and m, p, and s are independently selected from integers from 1 to 120. The compound is useful as a liver asialoglycoprotein receptor-targeted therapeutic agent in the form of a lipid nanoparticle, a liposome or a micelle including a drug or oligonucleotide.
Resumen de: AU2024296025A1
The present invention relates to a cerium oxide nanocomposite, a method for preparing same, and a composition for the prevention or treatment of inflammatory or autoimmune diseases, comprising same as an active ingredient. The present invention can be used as an excellent therapeutic composition in which both biostability and in vivo efficiency of scavenging reactive oxygen species are maximized by modifying the surface of cerium oxide nanoparticles with an optimal amount of a pyrrolidone derivative polymer. Also, the method for preparing the nanocomposite, of the present invention, can form uniform particles having an optimal diameter while completely removing toxicity caused by reaction residues and nitrate by only a simple process of washing with a sodium chloride solution having a specific concentration. The present invention can be usefully applied to an excellent therapeutic composition which significantly inhibits inflammatory responses in various tissues, and particularly, minimizes damage to nerve cells, caused by excessive inflammatory responses in the periphery of hematoma due to intracerebral hemorrhage, thereby restoring neurological functions and greatly improving the survival rate of patients.
Resumen de: AU2024290779A1
The present invention generally relates to the field of ionizable (also termed cationic) lipids, and in particular provides a novel type of such lipids as represented by formula (I). The present invention further provides methods for making such lipids as well as uses thereof, in particular in the preparation of nanoparticle compositions, more in particular nanoparticle compositions comprising active agents. It further provides pharmaceutical formulations comprising nanoparticle compositions based on the ionizable lipids disclosed herein.
Resumen de: AU2024304918A1
Poly(oxazoline) conjugates with pendant cationic groups (cationic POZ) and lipid nanoparticles (LNPs) including cationic POZ used to facilitate delivery of an encapsulated payload. LNPs and polyplexes including cationic POZ and a nucleic acid payload such as, but not limited to, mRNA or modified mRNA are disclosed. Such LNPs have no immunogenicity or reduced immunogenicity as compared to a corresponding LNP containing an ionizable lipid.
Resumen de: US20260053945A1
The present invention relates to an engineered disulphide-linked ferritin assembly comprising at least one modified ferritin subunit, wherein the at least one modified ferritin subunit comprises the amino acid sequence set forth in SEQ ID NO: 1, and comprises i) a F116H substitution, and zero or more amino acid substitutions at one or more positions selected from the group comprising E65, E128, E131, and D138 of SEQ ID NO: 1, and ii) a Cys substitution at two or more positions selected from the group comprising G37, L53, R66, G67, A74, A117 and A152 of SEQ ID NO: 1. The present invention also relates to its uses and manufacture.
Resumen de: WO2026042111A1
This invention, entitled "Temperature- and pH-Sensitive BPA-Targeted Chitosan-Poly(N-isopropylacrylamide)-FPBA Core-Shell Polymeric Nanoparticles Capable of Forming COF Structures in the BNCT Therapeutic Method," pertains to an anti-cancer pharmaceutical composition utilizing novel drug delivery methods. The application of the novel BNCT method is advantageous for cancers such as glioblastoma due to the challenge of crossing the blood-brain barrier. BNCT is a dual and targeted method wherein cancer cells, following the accumulation of ¹⁰B, are irradiated with thermal neutrons. Loading boron-containing compounds into nanoparticles can deliver a high concentration of boron to human glioblastoma cells. Temperature- and pH-sensitive nanoparticles of succinylated chitosan-poly(N-isopropylacrylamide) targeted with BPA are our concept for achieving endocytosis via sialic acid receptors on the surface of glial cells and for the targeted delivery of boron to these cells. By designing temperature- and pH-sensitive, BPA-targeted Chitosan-Poly(N-isopropylacrylamide)-FPBA core-shell polymeric nanoparticles with the capability of forming COF structures in order to simultaneously deliver BPA and FPBA, we aim to utilize the polymeric boron content to perform treatment via the BNCT method. Consequently, damage to healthy cells is reduced to a minimum, and even to zero.
Resumen de: WO2026042074A1
The present invention provides urea, ester and amide lipids and lipid nanoparticle compositions comprising these urea, ester and amide lipids, alone or in combination with other lipids. These lipid nanoparticles may be formulated with nucleic acids to facilitate their intracellular delivery both in vitro and for in vivo therapeutic applications. The lipids of the present invention are characterized as particularly hydrolytically and alcoholytically stable and were found to specifically target the lungs.
Resumen de: US20260053732A1
A method for extracting metal cations from a biological fluid of a subject in need thereof employs dialyzing the subject with a dialysis device. The dialysis device includes a porous dialysis membrane, and a reservoir containing a perfusion fluid. At least one chelator which is either grafted on polymers or grafted on nanoparticles is present in the perfusion fluid. The cut-off threshold of the porous membrane is lower than the mass of the polymer or the nanoparticles to which the chelator is grafted. Metal cations from a biological fluid of a subject are extracted by complexing to the chelator during dialysis.
Resumen de: WO2026044248A1
Aspects of the present disclosure provide for improved compositions of bioreducible and/or hydrolysable ionizable lipid nanoparticles useful for the delivery of therapeutic nucleic acids and other compounds to cells. Anionic phospholipids, including phosphatidylserine and phosphatidylglycerol can be included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells.
Resumen de: WO2026043843A1
The present disclosure is concerned with tetrahydropyrimidine (THP) ionizable lipids and lipid nanoparticle (LNP) formulations. The disclosed compounds and LNP formulations can be useful in the delivery of therapeutic agents such as, for example, mRNA for treatment of a viral infection, cancer, or a genetic disease or disorder. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Resumen de: WO2026044002A1
A nanoparticle vaccine composition includes a shell including one or more amphiphilic molecules and one or more hapten molecules, where at least one amphiphilic molecule is conjugated to the hapten molecule, and a substantially hydrophobic core including an immunogenic protein, a vaccine adjuvant, one or more inert biocompatible materials, or a combination of two or more thereof, where the core is encapsulated in the shell to form a nanoparticle.
Resumen de: WO2026042870A1
Disclosed are: lipid nanoparticles in which a nucleic acid having a length of 10 kb or more and a cationic substance are encapsulated; a nucleic acid delivery composition and a pharmaceutical that contain the aforementioned lipid nanoparticles; and a method for delivering a nucleic acid into a cell, the method comprising a step for bringing the aforementioned nucleic acid delivery composition into contact with a cell.
Nº publicación: WO2026041133A1 26/02/2026
Solicitante:
SHANGHAI CIRCODE BIOMED CO LTD [CN]
SHANGHAI CIRCODE BIOMED CO., LTD
Resumen de: WO2026041133A1
A pharmaceutical composition comprising a nucleic acid and a lipid compound of Formula (I). The pharmaceutical composition is used for delivering a nucleic acid to the spleen of a subject.
BOPI
Sede Electrónica
